我們已在上線! 進一步了解
6.25 USD
-0.05
0.79%
收盤時 已更新 10月16日 下午4:00 EDT
1天
-0.79%
5天
1.3%
1個月
21.83%
3個月
-6.16%
6個月
-5.16%
今年迄今
-5.73%
1年
-26.56%
5年
-84.87%
10年
-88.91%
 

關於: Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

員工: 753

新聞

正面
中性
負面
市場情緒 3個月
正面 10%
中性 60%
負面 30%
中性
Business Wire
昨天
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026.
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
中性
Business Wire
16 天前
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH.
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
中性
Zacks Investment Research
上個月
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
正面
Zacks Investment Research
2 個月前
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
負面
Zacks Investment Research
2 個月前
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
中性
Zacks Investment Research
2 個月前
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
中性
Seeking Alpha
2 個月前
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
負面
MarketBeat
2 個月前
Inogen Q2 Earnings Call Highlights
Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.
Inogen Q2 Earnings Call Highlights
負面
Zacks Investment Research
2 個月前
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
中性
Business Wire
2 個月前
Inogen Announces Second Quarter 2026 Financial Results
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Reported second quarter revenue of $95.1 million. Company raises full-year adjusted EBITDA guidance to approximately $4.0 million.
Inogen Announces Second Quarter 2026 Financial Results
價格圖表採用Lightweight Charts™實作